NRL 2025: Jarryd Hayne’s body transformation stuns ahead of rugby league return
Jarryd Hayne is looking in excellent shape as he gears up to return to make his football return.…
Kamaru Usman hopes UFC concurs with him on welterweight title shot
Kamaru Usman believes his most recent win should’ve eased any concerns about his standing as a top contender…
Where to watch Packers-Eagles MNF: Time, NFL schedule
NFL midseason superlatives: The biggest busts so far USA TODAY Sports’ Joe Rivera and Chris Bumbaca dish out…
Blue Origin to launch giant New Glenn rocket again. How to watch
On the eve of the scheduled launch window opening up, here’s how to watch a livestream as the…
CREATE Medicines Announces Positive First-in-Human Results for MT-302
Data demonstrates proof -of-mechanism for In Vivo CAR therapy in solid tumors CAMBRIDGE, Mass., Nov. 7, 2025 /PRNewswire/…
A decade after Mariana dam collapse, COP30 tests Brazil’s commitment to environmental justice
BOGOTA, Colombia (AP) — A week before what the Indigenous Krenak people now call “the death of the…
Tylenol, Kleenex, Band-Aid and more put under one roof in $48.7 billion consumer brands deal
Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a…
FDA’s top drug regulator resigns after federal officials probe ‘serious concerns’
WASHINGTON (AP) — The head of the Food and Drug Administration’s drug center abruptly resigned Sunday after federal…
Lee Soo Man: How the ‘King of K-pop’ built a global industry
SEOUL, South Korea (AP) — Lee Soo Man resisted the title at first. “King of K-pop” sounded too…
How to survive financially after a lay off
How to survive a layoff and protect your finances As more Americans are losing their jobs, these tips…
FDA Issues Formal Guideline Waiving Clinical Efficacy Studies for Biosimilars, Confirming Professor Niazi’s 15-Year Campaign to Cut Biologic Drug Costs
A Landmark Regulatory Shift Validates Professor Sarfaraz K. Niazi’s Vision to Make Biologics as Affordable as Generics CHICAGO,…
CREATE Medicines and Amsterdam University Medical Center Initiate First In Vivo CAR Therapy Trial in Frontline Setting for Solid Tumors
MT-302, a TROP2-targeting mRNA-LNP in vivo CAR therapy, is the first treatment of its kind to move into a…